<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195906</url>
  </required_header>
  <id_info>
    <org_study_id>SNF2017-06</org_study_id>
    <nct_id>NCT04195906</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of SNF472 for Calciphylaxis</brief_title>
  <acronym>Calciphyx</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanifit Therapeutics S. A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanifit Therapeutics S. A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives are to assess the efficacy, safety, and tolerability of SNF472
      compared to placebo when added to background care for the treatment of calciphylaxis (CUA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The formation and growth of calcified deposits in arterioles and other small blood vessels
      appears to be fundamental to the development of CUA especially in end stage renal disease
      patients. This phase 3 double-blind, randomized, placebo-controlled study is designed to
      assess the effect of SNF472 when added to background care to improve wound healing, as
      evaluated using Bates-Jensen Wound Assessment Tool (BWAT) scoring and pain as reported by the
      subject using a VAS scale. The study consists of a double-blind, randomized, placebo
      controlled period of 12 weeks followed by an open-label period of 12 weeks.. .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the BWAT-CUA score for the primary lesion</measure>
    <time_frame>Basline to week 12</time_frame>
    <description>The Bates Jensen Wound Assessment Tool (BWAT) CUA score ranges from a minimum score of 8 (best) to a maximum score of 40 (worst)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain VAS score</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Pain Visual Analog Scale (VAS) score ranges from a minimum score of 0 (no pain) to 100 (worst possible pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Wound-QoL score</measure>
    <time_frame>Basline to Week 12</time_frame>
    <description>The Wound Quality of Life scale is a validated self-assessment tool that has been shown to be feasible for assessing health-related quality of life in patients with chronic wounds. Lower scores are associated with a better quality of life as reported by the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the BWAT total score for the primary lesion</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Bates Jensen Wound Assessment Tool (BWAT) score ranges from a minimum score of 9 (best) to a maximum score of 65 (worst) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative wound image evaluation for the primary lesion</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in opioid use as measured in morphine milligram equivalents (MME)</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Calciphylaxis</condition>
  <condition>Calcific Uremic Arteriolopathy</condition>
  <arm_group>
    <arm_group_label>SNF472 (Double-Blind Period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Double-Blind Period)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo (saline) diluted in 100 mL physiological saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SNF472 (Open-Label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 7 mg/kg SNF472 diluted in 100 mL physiological saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: SNF472</intervention_name>
    <description>Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks</description>
    <arm_group_label>SNF472 (Double-Blind Period)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: Placebo</intervention_name>
    <description>Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks</description>
    <arm_group_label>Placebo (Double-Blind Period)</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimatenl SNF472 (Open-label)</intervention_name>
    <description>Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks</description>
    <arm_group_label>SNF472 (Open-Label)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male subjects, 18 years of age or older

          -  Receiving maintenance HD in a clinical setting for at least 2 weeks prior to screening

          -  Clinical diagnosis of CUA by the Investigator including ≥1 CUA lesion with ulceration
             of the epithelial surface

          -  CUA wound-related pain shown by a Pain VAS score ≥50 out of 100

          -  Primary lesion that can be clearly photographed for the purpose of protocol-specified
             wound healing assessments.

          -  Willing and able to understand and sign the informed consent form and willing to
             comply with all aspects of the protocol

        Exclusion Criteria:

          -  History of treatment with bisphosphonates within 3 months of baseline

          -  Severely ill subjects without a reasonable expectation of survival for at least 6
             months

          -  Subjects with a scheduled parathyroidectomy during the study period

          -  Expectation for kidney transplant within the next 6 months based on Investigator
             assessment or identification of a known living donor

          -  Pregnant or trying to become pregnant, currently breastfeeding, or of childbearing
             potential (including perimenopausal women who have had a menstrual period within one
             year) and not willing to comply with protocol required contraception criteria

          -  Significant noncompliance with dialysis

          -  History of active malignancy within the last year with the exception of localized
             basal cell or squamous cell carcinoma

          -  Clinically significant illness other than CUA within 30 days

          -  Participation in an investigational study and receipt of an investigational drug or
             investigational use of a licensed drug within 30 days prior to screening.

          -  History or presence of active alcoholism or drug abuse as determined by the
             Investigator within 6 months

          -  Mental impairment, current significant psychiatric disease, or other conditions or
             circumstances that would make the subject unlikely to complete the study or comply
             with the study procedures.

          -  Subjects whose CUA lesions exhibit significant improvement, in the opinion of the
             Investigator, between the first and second screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Gold, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanifit Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire S Padgett, PhD</last_name>
    <phone>+18589456542</phone>
    <email>Claire.Padgett@sanifit.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rekha Garg, MD, MS</last_name>
    <phone>+18589456542</phone>
    <email>rekha.garg@sanifit.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fresenius Kidney Care</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Maloney</last_name>
      <email>carolyn.maloney@frenovarenalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank C Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Medical Research Associates</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Karunaratne</last_name>
      <email>kanchana.cmra@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Renal Medical Group Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Padilla</last_name>
      <email>jesse.padilla@valleyrenal.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>06762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Kidney Care</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Maloney</last_name>
      <email>carolyn.maloney@frenovarenalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Kidney Care</name>
      <address>
        <city>McComb</city>
        <state>Mississippi</state>
        <zip>39648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Maloney</last_name>
      <email>carolyn.maloney@frenovarenalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Kidney Care</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>22704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Maloney</last_name>
      <email>carolyn.maloney@frenovarenalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Kidney Care</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Maloney</last_name>
      <email>Carolyn.maloney@frenovarenalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Kidney Care</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Maloney</last_name>
      <email>carolyn.maloney@frenovarenalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Terschan</last_name>
      <email>frank.terschan@davita.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calciphylaxis</keyword>
  <keyword>Calcific Uremic Arteriolopathy</keyword>
  <keyword>Wound</keyword>
  <keyword>ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calciphylaxis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

